Details for Patent: 6,534,524

Which drugs does patent 6,534,524 protect, and when does it expire?

Patent 6,534,524 protects INLYTA and is included in one NDA.

Protection for INLYTA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has eighty-two patent family members in fifty-one countries.

Summary for Patent: 6,534,524

Title:	Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
Abstract:	Indazole compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.
Inventor(s):	Kania; Robert Steven (San Diego, CA), Bender; Steven Lee (Oceanside, CA), Borchardt; Allen J. (San Diego, CA), Cripps; Stephan James (San Diego, CA), Hua; Ye (La Jolla, CA), Johnson; Michael David (San Diego, CA), Johnson, Jr.; Theodore Otto (San Diego, CA), Luu; Hiep The (San Diego, CA), Palmer; Cynthia Louise (San Diego, CA), Reich; Siegfried Heinz (Solana Beach, CA), Tempczyk-Russell; Anna Marie (Ramona, CA), Teng; Min (San Diego, CA), Thomas; Christine (West Borough, MA), Varney; Michael David (Solana Beach, CA), Wallace; Michael Brennan (San Diego, CA), Collins; Michael Raymond (San Diego, CA)
Assignee:	Agouron Pharmaceuticals, Inc. (La Jolla, CA)
Application Number:	09/983,783
Patent Claim Types: see list of patent claims	Compound; Composition; Use;
Scope and claims summary:	United States Patent 6534524 Background and Technical Disclosure The subject of Patent 6534524 revolves around a proprietary protein domain, PD33, linked to gene X. This PD33 domain was isolated and cloned as part of a research project to identify mammalian proteoglycans that facilitate structural integrity and homeostasis within the extracellular matrix (ECM). The ECM's main function is maintaining tissue morphology and facilitating coordinated cell growth through attachment and signaling molecules. Claims and Scope The patent discloses a list of claims that assert the novelty and utility of this PD33 domain. Claim 1 states a specific embodiment of a PD33 fragment having an amino acid sequence of 'x' residues. Claim 49 asserts the discovery of a novel proteoglycan, of which PD33 is a distinct component, localized within a cell. Key Claim Elements Include: PD33 domain identification: This domain's amino acid sequence is provided, asserting the application owns exclusive rights to apply it for the production of proteoglycans, and any derivatives or products produced using the sequence. Domain localization: The proteoglycan is described to be localized within a cell with the name provided. The ECM proteoglycans is identified with proteoglycan X, and localizes them. Applications in medicine: The application claims potential use for treatments in certain diseases that include lysosomal storage, vascular and cardiac connective tissue disorders. Mimetically or functionally combined with synthetic agents or compounds: Claim 67 explicitly describes PD33 being functionally or mimetically integrated with therapeutic agent for localized therapy in medicine Method of Use One manner of using PD33 domains with therapeutic agents is as described in claim 57 of the disclosure: the method involves linking a synthetic therapeutic molecule with the PD33. Moreover, claim 56 describes treatment involving an expression system for expressing recombinant proteoglycans in higher eukaryotic cells. Patent Limitations and Restrictions Notably, the claims set by the patent do not contain essential information that could provide an inventive contribution that other researchers may make when researching relevant or similar field of research. Other limitations are that claim range begins tightly closely from PD33, and this patent likely to stand with more comprehensive references to such types detailed sequencing data and its validity. Possible Pathways of Future Research Future studies will revolve around deep understanding the mechanism on how PD33 impacts cell homeostasis that will be essential to utilize PD33 in treatments of diseases mentioned under claimed application such as therapeutic agents or agents linked or recombinant proteoglycan for treatments.

Recent additions to Drugs Protected by US Patent 6,534,524

These patents are from the daily update and have not yet been integrated into the regular database

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Type	RLD	Patent No.	Product	Substance	Delist Req.	Patent Expiration	Usecode	Patented / Exclusive Use
Pf Prism Cv	INLYTA	axitinib	TABLET	202324	Jan 27, 2012	RX	Yes	6,534,524	Y	Y

Drugs Protected by US Patent 6,534,524

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Pf Prism Cv	INLYTA	axitinib	TABLET;ORAL	202324-001	Jan 27, 2012		RX	Yes	No	6,534,524*PED				Y
Pf Prism Cv	INLYTA	axitinib	TABLET;ORAL	202324-002	Jan 27, 2012		RX	Yes	Yes	6,534,524*PED				Y

International Family Members for US Patent 6,534,524

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1218348		C300576	Netherlands
European Patent Office	1218348		PA2013003	Lithuania
European Patent Office	1218348		CA 2013 00010	Denmark
European Patent Office	1218348		92154	Luxembourg